Equity Profile

MRNA

Moderna, Inc.

Health CareBiotechnology$18.8B

Jul31Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Moderna, Inc. is a biotechnology company focused on developing mRNA-based vaccines and therapeutics....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability, and investors will be keen to see if Moderna can narrow its losses this quarter.

N/A

Revenue Growth

Revenue figures will provide insight into the demand for Moderna's products and its ability to generate income outside of COVID-19 vaccines.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

MRNA Q2-2026 Earnings Preview

Context

Company Snapshot

Moderna, Inc. is a biotechnology company focused on developing mRNA-based vaccines and therapeutics. With a market cap of $19 billion, it plays a significant role in the healthcare sector, especially in response to infectious diseases and potential future pandemics.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+27.75%

Avg Stock Reaction

-3.15%

Last Quarter Recap

In Q1 2026, Moderna reported an EPS of -$3.40, missing expectations by 12.58%. The stock reacted negatively, declining 1.24% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Moderna's upcoming earnings are cautious, given its recent history of losses and lack of guidance.

Bull Case

If Moderna can show a significant reduction in losses and positive revenue growth, it may signal a turnaround and boost investor confidence.

Bear Case

Continued losses and disappointing revenue could lead to further declines in stock price, especially if the market is already pricing in a negative outlook.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS and how does it compare to previous quarters?

The EPS figure will be crucial in assessing whether Moderna is making progress in reducing its losses.

What revenue figures will be reported, and how do they reflect demand for Moderna's products?

Revenue growth is essential for understanding the company's financial health and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Moderna's potential for cost management and revenue diversification beyond COVID-19 vaccines.

Supporting Evidence

Historical performance shows a 75% EPS beat rate, indicating potential for positive surprises.

Options pricing suggests a significant move, which may reflect underlying investor uncertainty.

Recent quarters have shown volatility in stock reactions, indicating that the market may be overly cautious.

Key Risk

If EPS comes in below -$3.00, it could undermine the narrative of improving financial health.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether Moderna can effectively manage its costs and generate revenue growth amid ongoing challenges.

Bull Confirmed If

A reported EPS loss of less than $3.00 would indicate improved financial performance.

Bear Confirmed If

An EPS loss greater than $3.40 would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±16.5%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty about the earnings report.

Options are pricing ±16.5% while MRNA has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (790K)P/C Ratio: 0.12Puts (624K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Moderna beats EPS expectations, history suggests the stock could rise by around 3.3%, confirming a positive shift in investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.

Miss

If Moderna misses on EPS, history suggests a potential decline of around 1.1%, reinforcing concerns about its financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or pipeline advancements.
2Management's commentary on cost management strategies.
3Insights into demand for existing and future vaccines.
4Guidance on revenue expectations for the upcoming quarters.
5Responses to market competition and regulatory challenges.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul28

KNSABMO

Kiniksa Pharmaceuticals International, plc

PreviewView

Jul28

CURBBMO

Company Snapshot

Moderna, Inc. is a biotechnology company focused on developing mRNA-based vaccines and therapeutics....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability, and investors will be keen to see if Moderna can narrow its losses this quarter.

N/A

Revenue Growth

Revenue figures will provide insight into the demand for Moderna's products and its ability to generate income outside of COVID-19 vaccines.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

MRNA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+27.75%

Avg Stock Reaction

-3.15%

Last Quarter Recap

In Q1 2026, Moderna reported an EPS of -$3.40, missing expectations by 12.58%. The stock reacted negatively, declining 1.24% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Moderna's upcoming earnings are cautious, given its recent history of losses and lack of guidance.

Bull Case

If Moderna can show a significant reduction in losses and positive revenue growth, it may signal a turnaround and boost investor confidence.

Bear Case

Continued losses and disappointing revenue could lead to further declines in stock price, especially if the market is already pricing in a negative outlook.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS and how does it compare to previous quarters?

The EPS figure will be crucial in assessing whether Moderna is making progress in reducing its losses.

What revenue figures will be reported, and how do they reflect demand for Moderna's products?

Revenue growth is essential for understanding the company's financial health and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Moderna's potential for cost management and revenue diversification beyond COVID-19 vaccines.

Supporting Evidence

Historical performance shows a 75% EPS beat rate, indicating potential for positive surprises.

Options pricing suggests a significant move, which may reflect underlying investor uncertainty.

Recent quarters have shown volatility in stock reactions, indicating that the market may be overly cautious.

Key Risk

If EPS comes in below -$3.00, it could undermine the narrative of improving financial health.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether Moderna can effectively manage its costs and generate revenue growth amid ongoing challenges.

Bull Confirmed If

A reported EPS loss of less than $3.00 would indicate improved financial performance.

Bear Confirmed If

An EPS loss greater than $3.40 would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±16.5%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty about the earnings report.

Options are pricing ±16.5% while MRNA has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (790K)P/C Ratio: 0.12Puts (624K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Moderna beats EPS expectations, history suggests the stock could rise by around 3.3%, confirming a positive shift in investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.

Miss

If Moderna misses on EPS, history suggests a potential decline of around 1.1%, reinforcing concerns about its financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or pipeline advancements.
2Management's commentary on cost management strategies.
3Insights into demand for existing and future vaccines.
4Guidance on revenue expectations for the upcoming quarters.
5Responses to market competition and regulatory challenges.